Computer assisted design of second-generation colchicine derivatives

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Pharmacology

Background:

• Cytoskeletal proteins like tubulin are crucial targets for anti-cancer drugs.
• Differential expression of beta-tubulin isotypes in normal versus cancerous cells offers a strategy for targeted chemotherapy.
• Colchicine is a known tubulin-binding agent, but its derivatives may offer improved specificity and potency.

Purpose of the Study:

• To design and synthesize novel colchicine derivatives with enhanced affinity for beta-tubulin isotypes.
• To evaluate the anti-cancer potential of these derivatives through cytotoxicity assays.
• To establish a foundation for developing second-generation derivatives based on promising first-generation scaffolds.

Main Methods:

• Computational probing of designed colchicine derivatives for binding affinity to beta-tubulin isotypes.
• Chemical synthesis of promising colchicine derivatives.
• In vitro cytotoxicity assays to determine half-maximal inhibitory concentration (IC50) values.

Main Results:

• Several first-generation colchicine derivatives were synthesized and tested.
• Promising compounds exhibited IC50 values approximately 30-fold lower than those of colchicine.
• Preliminary computational screening of second-generation derivatives based on these scaffolds was performed.

Conclusions:

• First-generation colchicine derivatives demonstrate significant potential as anti-cancer agents.
• The developed compounds show improved potency compared to the parent drug, colchicine.
• This work provides a basis for the rational design of more effective, isotype-specific anti-cancer therapeutics.